CMV prophylaxis in hematopoietic-cell transplantation

New England Journal of Medicine

Volumn 371, Issue 6, 2014, Pages 576-577

  Romee, Rizwan ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD57 ANTIGEN; LETERMOVIR; LYMPHOCYTE RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2C; UNCLASSIFIED DRUG;

CELL EXPANSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFECT; DRUG MECHANISM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; LETTER; MYELOID LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT INDICATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 84905918867     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1406756     Document Type: Letter

References (5)

1. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 2014;370:1781-9.
2. Elmaagacli AH, Koldehoff M, Lindemann M, et al. Response: T cells are required for the CMV-induced antileukemia effect after transplant. Blood 2012;119:1090-1.
3. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood 2013;122:1316-24.
4. Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014;20:46-52.
5. Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012;119:2665-74.